TREATMENT OF NTRK GENE FUSION TUMORS: LAROTRECTINIB TO BE AVAILABLE IN JAPAN
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Bayer has recently submitted a sales license application for larotrectinib to Japan's Ministry of Health, Labour and Welfare (MHLW)Larotrectinib is an oral TRK inhibitor used to treat late-stage or metastatic solid tumors with rare genomic changes: gene fusion of neurotrophic tyrosine receptor kinase (NTRK)Larotrectinib has been approved for listing in the US, Brazil, Canada and the European Union"Larotrectinib has the potential to significantly improve treatment outcomes regardless of the type of tumor in the patient or the patient's age," said DrScott ZFields, senior vice president and head of oncology development at BayerLarotrectinib represents an important advance in the fight against this rare cancer, as it can replace expensive treatments that are not specific to the cancer."submissions to MHLW are based on clinical data from Phase I trials in adult patients, Phase II trials based on adult and adolescent patients, and ScoutNAVIGATE trials in Phase I/IIIn these trials, the effectiveness and safety of larotrectinib in treating more than 20 different solid tumors, including lung, thyroid, melanoma, gastrointestinal mesoplasmic, colon, bile duct cancer, and soft tissue sarcoma, were explored
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
